Protocol Title: A Randomized, Phase III, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Target Population: Locally Advanced or Metastatic Renal Cell Carcinoma (RCC)

Summary: In this randomized, Phase III, double-blind, placebo-controlled study, patients will be randomized 2:1 to receive either a combination of Pazopanib plus Abexinostat or Pazopanib plus placebo.

Key Inclusion Criteria:
- Patients aged ≥ 18 years at time of study entry.
- Histologically confirmed RCC with clear cell component.
- Locally advanced and unresectable or metastatic disease.
- Measurable disease as assessed only by the investigator according to RECIST version 1.1.
- Must not have had any prior VEGF tyrosine kinase inhibitor treatment in either (neo)adjuvant or locally advanced/metastatic setting.
  - Up to 1 line of prior cytokine or immune checkpoint inhibitor treatment is allowed in either the (neo)adjuvant or metastatic setting provided screening scans indicate progressive disease (PD) during or following completion of treatment.
- ECOG Performance Status of 0 or 1.
- Adequate baseline organ and hematologic function.
- Must be at least 2 weeks from last systemic treatment or dose of radiation prior to date of randomization.

Key Exclusion Criteria:
- Persistent clinically significant toxicities (Grade ≥ 2; per NCI CTCAE version 5 from previous anticancer therapy (excluding alopecia which is permitted and excluding Grades 2 and 3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the investigator, and can be managed with available medical therapies).
- Untreated CNS metastases.
  - Patients with treated CNS metastases are eligible provided imaging demonstrates no new or progressive metastases obtained at least 4 weeks following completion of treatment.
  - CNS imaging during Screening is not required unless clinically indicated.
- Additional malignancy requiring treatment within the past 3 years.
  - Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, and non-muscle invasive urothelial carcinoma.
- Poorly controlled hypertension, defined as systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 100 mmHg.
  - Use of anti-hypertensives and rescreening is permitted.
- A new pulmonary embolism or deep venous thrombosis diagnosed within 3 months prior to randomization.
- Has a QTcF interval > 480 msec.
- New York Heart Association Class III or IV congestive heart failure.
- Use of prohibited medication within 7 days or 5 half-lives, whichever is shorter, prior to first dose of study drug.

Contacts:
- Principal Investigator: Marc Matrana, MD
- Research Nurses (RN): Jessica Rentfrow (jessica.rentfrow@ochsner.org, ext. 32652)
  Amanda Struckhoff (amanda.struckhoff@ochsner.org, ext. 23682)

For additional information: https://clinicaltrials.gov/ct2/show/NCT03592472